We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Microbiota’s Role Explored in Colorectal Cancer Among the Young

By LabMedica International staff writers
Posted on 06 Feb 2020
Print article
Image: Photomicrograph of the bacterium, Fusobacterium nucleatum:  gram-negative stained from culture (Photo courtesy of J. Michael Miller, PhD, (D)ABMM)
Image: Photomicrograph of the bacterium, Fusobacterium nucleatum: gram-negative stained from culture (Photo courtesy of J. Michael Miller, PhD, (D)ABMM)
Colorectal cancer incidence has been declining for several decades in people over 55, in part because of the increased use of screening for the disease, particularly with colonoscopy which can find and remove polyps before they become cancerous.

However such screenings are generally not recommended for people under age 50, but colorectal cancer rates have been increasing at nearly a 2% annual rate in people under age 55 since 2006. There are many theories about why, including a rise in obesity, diabetes, and diets low in whole grains among younger people.

Bacteria typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly four-fold higher rate in people over 75 than in those under 45 years of age, pointing out how differences in the bacteria that comprise what is known as the body's microbiome could affect cancer outcomes to varying degrees.

Oncologists at the Georgetown Lombardi Comprehensive Cancer Center (Washington, DC, USA) analyzed the role of the microbiome in colorectal cancer. To do this they looked at the DNA and microbiome of archived tumors, as well as adjacent normal tissue when available, from 31 patients with colorectal cancer who were diagnosed before the age of 45 or after the age of 65.

Scientists have known that certain microbes that comprise the microbiome, which consists of different types of bacteria, fungi and viruses, can disturb the lining of the colon and promote tissue inflammation. This can result in mutations to the DNA of cells in the colon and lead to cancer. Scientists also know that F. nucleatum can promote cancerous growth by suppressing immune responses in the colon.

Overall, the investigators found 478 unique bacterial and fungal species in the tumors. One of the most common bacteria found was F. nucleatum, which appeared in five of the younger patients' tumors and in three of the older patients' tumors. The team also found a significant difference in the rate of Moraxella osloensis (11% versus 46%) in younger compared to older patients.

Benjamin Adam Weinberg, MD, an assistant professor of medicine and a senior author of the study, said, “There was a much higher presence of F. nucleatum in younger patients than we expected. We haven't seen large genetic differences in colorectal tumors from younger versus older people, so we hypothesize that something else, perhaps the microbiome, is contributing to the rise in incidence of the disease in younger people.” The study was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium held January 23-25, 2020 in San Francisco, CA, USA).

Related Links:
Georgetown Lombardi Comprehensive Cancer Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.